Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
Tenenbaum A, Fisman EZ
Cardiovasc Diabetol 2004 Dec 1, 3:10
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

BioMed Central articles that cite the above article:

1.


Review    
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
Tenenbaum A, Fisman EZ, Motro M, Adler Y
Cardiovascular Diabetology 2006, 5:20 (26 September 2006)
 [Abstract] [Full Text] [PDF] [PubMed] [Related articles]
2.


Editorial    
Statins research unfinished saga: desirability versus feasibility
Fisman EZ, Adler Y, Tenenbaum A
Cardiovascular Diabetology 2005, 4:8 (7 June 2005)
 [Abstract] [Full Text] [PDF] [PubMed] [Related articles] [Cited on BioMed Central]
printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.